Davis's Drug Guide
abrocitinib
General
Genetic Implications:
Pronunciation:
a-broe-sye-ti-nib
Trade Name(s)
- Cibinqo
Ther. Class.
anti-inflammatories
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Abrocitinib." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110937/all/abrocitinib.
Vallerand AHA, Sanoski CAC, Quiring CC. Abrocitinib. Davis's Drug Guide. F.A. Davis Company; 2023. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110937/all/abrocitinib. Accessed April 27, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Abrocitinib. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110937/all/abrocitinib
Vallerand AHA, Sanoski CAC, Quiring CC. Abrocitinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2024 April 27]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110937/all/abrocitinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - abrocitinib
ID - 110937
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110937/all/abrocitinib
PB - F.A. Davis Company
ET - 18
DB - Nursing Central
DP - Unbound Medicine
ER -
